Augurex and New Day Diagnostics Launch SPINEstat™

New Day Diagnostics has a recently-published press release announcing their new collaboration to launch SPINEstat™, a biomarker assay that will help manage akylosing spondylitis (AS), a very serious form of spinal arthritis. This blood test works to detect the auto-antibodies present in AS and distinguish them from those causing other types of back pain—something that with traditional testing can take 10 years on average to diagnose. This is the first easily accessible blood test for AS!

From Eric Mayer, CEO of New Day Diagnostics:

“We are excited to work with Augurex to develop and bring their novel SPINEstat™ test for AS to physicians. This technology aligns with our multiplex development expertise and more importantly with our company’s mission to introduce specialized, innovative and accessible chronic disease diagnostic tests that empower individuals for improved healthcare.”

We are proud to be among the investors supporting New Day Diagnostics’ development of these technologies. Read the full press release below.